Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients. Issue 5 (May 2022)

• Record Type: Journal Article
• Authors: Al-Ani, Mohammad A.; Murray, Melissa R.; Taha, Mohamad Badie; Meece, Lauren; Elsayed, Abdelrahman H.; Jeng, Eric I.; Arnaoutakis, George J.; Wu, Yu; Friedman, Jeffrey E.; Vilaro, Juan R.; Parker, Alex M.; Aranda, Juan M.; Ahmed, Mustafa M.
• Is Part Of: Journal of cardiovascular pharmacology. Volume 79:Issue 5(2022)
• Page Start: 646
• Page End: 649
• Publication Date: 2022-05
• Subjects: left ventricular assist device -- laparoscopic sleeve gastrectomy -- cardiovascular pharmacotherapy; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000001223
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract: Left ventricular assist device (LVAD) implantation is increasingly utilized in patients with advanced heart failure and morbid obesity. Laparoscopic sleeve gastrectomy (LSG) can facilitate weight loss in this population and can ultimately change the pharmacokinetics of heart failure therapeutics. In this study, we aimed to explore the changes in cardiovascular pharmacotherapy post LSG intervention. We conducted a retrospective observational cohort study of morbidly obese LVAD patients between 2013 and 2019 at the University of Florida with available pharmacotherapeutic data at 1 and 6 months. Thirteen post-LSG patients and 13 control subjects were included in the final analysis. In the post-LSG group, the mean body mass index decreased significantly (44 ± 5 vs. 34 ± 4.9, P < 0.001), and 7 patients were successfully bridged to cardiac transplantation. Only 3 patients required adjustment of their LVAD speed. Mean return to flow decreased by 8 mm Hg, despite a 45% reduction in the mean number of vasodilators per patient (1.2 vs. 0.7, P = 0.03). Mean weekly warfarin dose decreased by 35% after 6 months (32.9 ± 20.9 vs. 50.7 ± 26.6, P = 0.01). The use of diuretics, vasodilators, and beta-blockers was significantly reduced by 50%, 45%, and 35%, respectively. None of these changes were observed in the control group at 6-month follow-up post LVAD. In this single-center experience, weight loss post LSG is associated with decreased vasodilator, diuretic, and anticoagulant medication requirements in LVAD patients.